1. Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. (December 2016) Authors: André, F.; Stemmer, S.M.; Hortobagyi, G.N.; Burris, H.A.; Paluch-Shimon, S.; Campone, M.; Villanueva, C.; Chan, A.; Wist, E.; Marschner, N.; Bachelot, T.; Blau, S.; Janni, W.; Verma, S.; Conte, P.; Dhuria, S.; Yang, S.; Stegert, M.; Germa, C.; Arteaga, C.L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗